

FORM PTO-1449 (REV. 7-97)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.		FILING DATE: October 21, 2003	
MAY 18 2007 PATENT & TRADEMARK OFFICE		GROUP: 1615					

U.S. PATENT DOCUMENTS												
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE						
<i>JS</i>	AA	3 9 6 5 2 5 6	06/22/1976 Leslie	424	22							
	AB	4 2 3 7 1 4 0	12/02/1980 Dudzinski	424	260							
	AC	4 3 6 6 3 1 0	12/28/1982 Leslie	536	56							
	AD	4 4 4 3 4 2 8	04/17/1984 Oshlack, et al.	424	22							
	AE	4 8 2 8 8 3 6	05/09/1989 Elger, et al.	424	419							
	AF	4 8 3 4 9 6 5	05/30/1989 Martani, et al.	424	488							
	AG	4 8 3 4 9 8 4	05/30/1989 Goldie, et al.	424	488							
	AH	4 8 3 4 9 8 5	05/30/1989 Elger, et al.	424	488							
	AI	4 8 4 4 9 0 7	07/04/1989 Elger, et al.	424	465							
	<i>JS</i>	AJ	4 8 4 4 9 0 9	07/04/1989 Goldie, et al.	424	480						

FOREIGN PATENT DOCUMENTS												
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION							
					YES	NO						
<i>JS</i>	AK	0 1 9 3 3 5 5	09/03/1986 Europe (A3)	A61K	31/615							
	AL	0 3 1 9 2 4 3	06/07/1989 Europe (A1)	A61K	31/485							
	AM	0 3 1 9 2 4 3	11/07/1990 Europe (A2)	A61K	31/485							
	AN	0 0 0 1 3 7 7	01/13/2000 WO	A61K	31/00							
	<i>JS</i>	AO	9 0 0 4 9 6 5	05/17/1990 WO	A61K	31/485						


  

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)	
<i>JS</i>	AP Translation of previously submitted German patent application DE 43 25 465 1995
<i>JS</i>	AQ Alvarez-Fuentes, et al., "Effectiveness of Repeated Administration of a New Oral Naltrexone Controlled-Release System on Morphine Analgesia"; J. Pharm Pharmacol (2001), 53; pg. 1201-1205
<i>JS</i>	AR Alvarez-Fuentes, et al., "Preclinical Study of an Oral Controlled Release Naltrexone Complex in Mice"; J. Pharm Pharmacol (2000), 52; pg. 659-663


  


EXAMINER <div style="font-family: cursive; font-size: 1.5em; margin-top: 10px;"> <i>Sumner J. Davis</i> </div>	DATE CONSIDERED <div style="font-family: cursive; font-size: 1.5em; margin-top: 10px;"> <i>7/23/07</i> </div>
---	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866							
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.									
				FILING DATE: October 21, 2003		GROUP: 1615							
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL	BA	DOCUMENT NUMBER			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
q/s		4	8	4	4	9	1	0	07/04/1989	Leslie, et al.	424	494	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION				
									YES	NO			
	BB												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
q/s	BC	Archer, Sydney; "Historical Perspective on the Chemistry and Development of Naltrexone"; Naltrexone: Research Monograph 28 (1980) pg. 3-9											
	BD	Baum, et al., "The Impact of the Addition of Naloxone on the Use and Abuse of Pentazocine"; Public Health Reports (1987) Vol. 102, No. 4 pg. 426-429											
	BE	Rapaka, et al., "Discovery of Novel Opioid Medications"; NIDA Research Monograph 147 (1995) pg. 53-83											
	BF	Bloom, et al., "Clinical Studies with Naloxone/Methadone in a Ratio of 1:20"; 5 <sup>th</sup> National Conference on Methadone Treatment (1973) Vol. 2, pg. 1342 - 1349											
	BG	Blachly, M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pg. 209-213											
	BH	Briscoe, et al., "Methoclocinnamox: Time Course of Changes in Alfentanil-Reinforced Responding in Rhesus Monkeys"; Psychopharmacology (2000) 148: pg. 393-399											
	BI	Abstract of Bromm, et al., "A Sensitive Method to Evaluate Effects of Analgesics in Man"; Meth and Find Exptl Clin Pharmacol 5 (8) (1983) pg. 545-551											
	BJ	Bullingham, et al., "Clinical Pharmacokinetics of Narcotic Agonist-Antagonist Drugs"; Clinical Pharm. (1983) 8: 332-343											
	BK	Calimlim, et al., "Effect of Naloxone on the Analgesic Activity of Methadone in a 1:10 Oral Combination"; Clin Pharmacol and Thera (1974) Vol. 15; No. 6 pg. 556-564											
	BL	Caruso, et al., "Methadone and Naloxone in Combination (Naldone®) for the Treatment of Heroin Addicts"; Bristol Laboratories, pg. 1336-1341F 1973											
	BM	Cherny, Nathan I., "Opioid Analgesics"; Drugs (1996) May: 51 (5) pg. 713-737											
	BN	Chiang, et al., "Clinical Evaluation of a Naltrexone Sustained-Release Preparation"; Drug and Alcohol Dependence (1985) 16, pg. 1-8											
	BO	Chiang, et al., "Kinetics of a Naltrexone Sustained-Release Preparation"; Clin. Pharmacol Thera (1984) Vol. 36, No. 5, pg. 704-708											
	BP	Comer, et al., "Depot Naltrexone: Long-lasting Antagonism of the effects of heroin in humans"; Psychopharmacology (2002) 159; pg. 351-360											
q/s	BQ	Crabtree, et al., "Review of Naltrexone, a long-acting opiate antagonist"; Clinical Pharmacy, Vol 3 (1984) pg. 273-280											
EXAMINER						DATE CONSIDERED							
						07/23/07							
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866							
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.									
				FILING DATE: October 21, 2003		GROUP: 1615							
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
q/s	CA	4	8	6	7	9	8	5	09/19/1989	Heafield, et al.	424	461	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
	CB												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
q/s	CC	Crain et al., "Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability"; Dept. Of Neuroscience, Albert Einstein College of Medicine, Pain 82 (1999) pg. 1-11											
	CD	Crain et al., "Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability"; Dept. Of Neuroscience, Albert Einstein College of Medicine, Pain 84 (2000) pg. 121-131											
	CE	Fink, et al., "Naloxone in Heroin Dependence"; Clin Pharm and Therapeutics, Vol 9, No. 5; pg. 568-577 1968											
	CF	Fishman, et al., "Disposition of Naloxone-7,8- <sup>3</sup> H in Normal & Narcotic-Dependent Men"; J. of Pharm. and Experimental Therapeutics (1973) Vol-187, No. 3, pg. 575-580											
	CG	Fraser, Albert D., et al., "Clinical Toxicology of Drugs Used in the Treatment of Opiate Dependency"; Clinical Toxicology I, (1990) Vol 10, No. 2, pg. 375-386											
	CH	Freye, et al., "Effects of Tramadol and Tilidine/Naloxone on Oral-Caecal Transit & Pupillary Light Reflex"; Arzneim.-Forsch/Drug Res. 50 (I) (2000) pg. 24-30											
	CI	Fudala, et al., "Effects of Burpenorphine and Naloxone in Morphine-Stabilized Opioid Addicts"; Drug and Alcohol Dependence 50 (1998) pg. 1-8											
	CJ	Fudala, et al., "Human Pharmacology and Abuse Potential of Nalmefene"; Clin Pharm and Thera (1991) Vol 49, 3, pg. 300-306											
	CK	Gal, et al., "Prolonged Blockade of Opioid Effect with Oral Nalmefene"; Clin Pharmacol Ther. (1986) pg. 537-542											
	CL	Gerra, et al., "Clonidine and Opiate Receptor Antagonists in the Treatment of Heroin Addiction"; J. Substance Abuse Treatment (1995) Vol 12, 1, pg. 35-41											
	CM	Ghodse, et al., "Opioid analgesics and narcotic antagonists"; Side Effects of Drugs (2000) Annual 23, Ch. 8, pg. 96-113											
	CN	Glatt, William, M.D. FACP, "A New Method for Detoxifying Opioid-Dependent Patients"; J. Substance Abuse Treatment (1999) Vol 17, No 3, pg. 193-197											
	CO	Gold, et al., "Rapid Opioid Detoxification during General Anesthesia"; Anesthesiology (1999) Vol 91, No 6, 1639-1647											
q/s	CP	Greenwald, et al., "Comparative Clinical Pharmacology of Short-Acting <i>Mu</i> Opioids in Drug Abusers"; J. Pharm. and Experimental Therapeutics (1996) Vol 277, No 3, pg. 1228-1236											
EXAMINER  J. Rivera y. Prieto									DATE CONSIDERED  7/23/07				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866							
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.									
				FILING DATE: October 21, 2003		GROUP: 1615							
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL	DA	DOCUMENT NUMBER				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
j/s		4	9	4	0	5	8	7	07/10/1990	Jenkins, et al.	424	480	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
										YES	NO		
	DB												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
j/s	DC	Gupta, et al., "Morphine Combined with Doxapram or Naloxone"; Anaesthesia (1974) Vol 29 pg. 33-39											
	DD	Richter, et al., "Clinical Investigation on the Development of Dependence during Oral Therapy with Tramadol"; Arzneim-Forsch/Drug Res. 35 (No II) (1985) pg. 1742-1744											
	DE	Rosen, et al., "Effect of Clonidine Pretreatment on Naloxone-Precipitated Opiate Withdrawal"; J. of Pharm. and Experimental Ther. (1996) Vol 276, No 3, pg. 1128-1135											
	DF	Rosen, et al., "The effect of lamotrigine on naloxone-precipitated opiate withdrawal"; Drug and Alcohol Dependence (1998) Vol 52, pg. 173-176											
	DG	Rosen, et al., "A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal"; European J. of Pharm. (1996) Vol 307, pg. 251-257											
	DH	Schuh, et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. of Pharm. and Experimental Ther. (1996) Vol 278, 2, pg. 836-846											
	DI	Schuh, et al., "Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans"; Psychopharmacology (1999) Vol 145, pg. 162-174											
	DJ	Stevens, et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions"; Psychopharmacology (1981) Vol 75, pg. 210-211											
	DK	Stine, et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance"; Am. J. Drug Alcohol Abuse (1994) Vol 20, (4), pg. 445-458											
	DL	Stine, et al., "Use of Drug Combinations in Treatment of Opioid Withdrawal"; J. of Clinical Psych. (1992) Vol 12, No. 3, pg. 203-209											
	DM	Stoller, et al., "Effects of buprenorphine/naloxone in opioid-dependent humans"; Psychopharmacology (2001) Vol 154, pg. 230-242											
	DN	Strain, et al., "Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. of Pharm. and Experimental Ther. (1992) Vol 261, No. 3, pg. 985-993											
	DO	Strain, et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pg. 374-383											
	DP	Strain, et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. of Pharm. and Experimental Ther. (1993) Vol 267, No 2, pg. 624-634											
	DQ	Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages											
j/s	DR	Umbricht, et al., "Naltrexone shortened opioid detoxification with buprenorphine"; Drug and Alcohol Dependence (1999) Vol 56, pg. 181-190											
EXAMINER							DATE CONSIDERED						
							7/23/07						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/589,866	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.			
				FILING DATE: October 21, 2003		GROUP: 1615	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL	EA	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
9/8		4 9 7 0 0 7 5	11/13/1990	Oshlack	424	451	
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	EB						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
9/8	EC	Vaccarino, et al., "Endogenous Opiates: 1999"; Peptides 21 (2000) pg. 1975-2034					
	ED	Wang, et al., "Inverse agonists and neutral antagonists at $\mu$ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence"; J. of Neurochemistry (2001) Vol 77, pg. 1590-1600					
	EE	Way, et al., "Responsivity to Naloxone during Morphine Dependence"; Annals New York Academy of Sciences, pg. 252-261 197					
	EF	Weinberg, et al., "Sublingual absorption of selected opioid analgesics"; Clin Pharm Ther (1988) Vol 44, No 3, pg. 335-342					
	EG	Wells, et al., "In Vivo Pharmacological Characterization of SoRI 9409, a Nonpeptidic Opioid $\mu$ -Agonists/ $\delta$ -Antagonist that Produces Limited Antinociceptive Tolerance and Attenuates Morphine Physical Dependence"; J. Pharm and Exper. Thera. (2001) Vol 297, No 2, pg. 597-605					
	EH	Wodak, Alex, "Drug Treatment for Opioid Dependence"; Australian Prescriber (2001) Vol 24, No 1, pg. 4-6					
	EI	Wright, et al., "Acute physical dependence in humans; repeated naloxone-precipitated withdrawal after a single-dose of methadone"; Drug and Alcohol Dependence (1991) Vol 27, pg. 139-148					
	EJ	Zhu, et al., "Naltrexone-precipitated morphine withdrawal in infant rat is attenuated by acute administration of NOS inhibitors but not NMDA receptor antagonists"; Psychopharmacology (2000) Vol 150, pg. 325-336					
	EK	Han, et al., "Mucoadhesive buccal disks for novel nalbuphine prodrug controlled delivery: effect of formulation variables on drug release and mucoadhesive performance"; International J. of Pharm (1999) Vol 177, pg. 201-209					
	EL	Handal, et al., "Naloxone"; Annals of Emergency Medicine (1983) Vol 12:7, pg. 438-445					
	EM	Harris, et al., "Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine"; Drug and Alcohol Dependence (2000) Vol 61, pg. 85-94					
	EN	Hawkes, et al., "Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine"; Aliment Pharm Ther (2001) Vol 15, pg. 625-630					
9/8	EO	Högger, et al., "Comparison of tilidine/naloxone, tramadol and bromfenac in experimental pain: a double-blind randomized crossover study in healthy human volunteers"; International J. Clin Pharm and Ther (1999) Vol 37, No 8, pg. 377-385					
EXAMINER				DATE CONSIDERED			
				07/23/07			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866								
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: October 21, 2003		GROUP: 1615								
<b>U.S. PATENT DOCUMENTS</b>														
*EXAMINER INITIAL	FA	FB	FC	FD	FE	FF	FG	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
								4 9 8 7 1 3 6	01/22/1991	Kreek, et al.	514	282		
								4 9 9 0 3 4 1	02/05/1991	Goldie, et al.	424	484		
								5 0 7 1 6 4 6	12/10/1991	Malkowska, et al.	424	497		
								5 0 9 1 1 8 9	02/25/1992	Heafield, et al.	424	457		
								5 2 1 5 7 5 8	06/01/1993	Krishnamurthy	424	488		
								5 2 2 6 3 3 1	07/13/1993	Thompson, et al.	73	865.9		
							5 2 6 6 3 3 1	11/30/1993	Oshlack, et al.	424	468			
<b>FOREIGN PATENT DOCUMENTS</b>														
								DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
								FH						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
	FI	Budd, Keith, "Clinical use of Opioid Antagonists"; Bailliere's Clinical Anesthesiology (1987) Vol 1, No 4, pg. 993-1011												
	FJ	Crain, et al., "Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment"; Proc. Natl. Acad. Sci (1995) Vol 92, pg. 10540-10544												
	FK	Howes, et al., "The Pharmacology of TR5109, a New Narcotic Agonist/Antagonist Analgesic"; NIDA Research (1979) pg. 99-105												
	FL	Leeling, et al., "Disposition and metabolism of codorphone in the rat, dog and man"; Drug Metabolism and Disposition (1982) Vol 10, No 6, pg. 649-653												
	FM	Amass, et al., "Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet"; Drug and Alcohol Dependence (2000) Vol 58, pg. 143-152												
	FN	Hussain, et al., "Buccal and oral bioavailability of naloxone and naltrexone in rats"; (1987) Vol 36, pg. 127-130												
	FO	Jasinski, et al., "The human pharmacology and abuse potential of N-allylnoroxymorphone naloxone"; J. of Pharm and Exper Thera (1967) Vol 157, No. 2, pg. 420-426												
	FP	Jones, et al., "Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans"; Drug and Alcohol Dependence (2000) Vol 60, pg. 29-37												
	FQ	Kanof, et al., "Clinical Characteristics of Naloxone-Precipitated Withdrawal in Human Opioid-Dependent Subjects"; J. of Pharm and Exper Thera (1992) Vol 260, No. 1, pg. 355-363												
	FR	King, et al., "Naltrexone Biotransformation and Incidence of Subjective Side Effects: A Preliminary Study"; Alcoholism: Clin and Exp Res (1997) Vol 21, No. 5, pg. 906-909												
	EXAMINER										DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866								
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: October 21, 2003		GROUP: 1615								
<b>U.S. PATENT DOCUMENTS</b>														
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	GA	5	2	8	6	4	9	3	02/15/1994	Oshlack, et al.	424	468		
	GB	5	3	2	4	3	5	1	06/28/1994	Oshlack, et al.	106	153		
	GC	5	3	3	6	6	9	1	08/09/1994	Raffa, et al.	514	629		
	GD	5	3	5	6	4	6	7	10/18/1994	Oshlack, et al.	106	153		
	GE	5	4	1	1	7	4	5	05/02/1995	Oshlack, et al.	424	456		
	GF	5	4	6	0	8	2	6	10/24/1995	Merrill, et al.	424	470		
	GG	5	4	7	2	7	1	2	12/05/1995	Oshlack, et al.	424	480		
	<b>FOREIGN PATENT DOCUMENTS</b>													
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	GH	8	7	0	1	2	8	2	03/12/1987	WO	A61K	31/485		
	GI	0	1	3	2	1	8	0	05/10/2001	WO (A2)	A61K	31/485		
	GJ	0	1	6	8	0	8	0	09/20/2001	WO (A2)	A61K	31/00		
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
	GK	Kogan, et al., "Estimation of the Systemic Availability and other Pharmacokinetic Parameters of Naltrexone in Man after Acute and Chronic Oral Administration"; Res. Comm. in Chem. Path. and Pharm (1977) Vol 18, No. 1, pg. 29-34												
	GL	Kosten, Thomas R., M.D., "Buprenorphine for Benzodiazepine-Abusing Heroin Addicts"; Amer J. of Psychiatry (1994) Vol 1, pg. 151												
	GM	Kosten, et al., "Opioid antagonist challenges in buprenorphine maintained patients"; Drug and Alcohol Dependence (1990) Vol 25, pg. 73-78												
	GN	Kurland, et al., "Naloxone and the Narcotic Abuser: A Controlled Study of Partial Blockade"; Inter. J. of the Addictions (1974) Vol 9, No. 5, pg. 663-672												
	GO	Lee, et al., "Nalbuphine Coadministered with Morphine Prevents Tolerance and Dependence"; Anesth Analg (1997) Vol 84, pg. 810-815												
	GP	Lehmann, et al., "Influence of Naloxone on the Postoperative Analgesic and Respiratory Effects of Buprenorphine"; Eur J. Clin. Pharm. (1988) Vol 34, 343-352												
	GQ	Levine, et al., "Potentiation of Pentazocine Analgesia by Low-dose Naloxone"; J Clin Invest. (1988) Vol 82, pg. 1574 - 1577												
EXAMINER 										DATE CONSIDERED 7/23/07				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.			
				FILING DATE: October 21, 2003		GROUP: 1615	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	HA	5 4 7 8 5 7 7	12/26/1995	Sackler, et al.	424	489	
	HB	5 5 0 0 2 2 7	03/19/1996	Oshlack, et al.	424	476	
	HC	5 5 0 8 0 4 2	04/16/1996	Oshlack, et al.	424	468	
	HD	5 5 0 8 0 4 3	04/16/1996	Krishnamurthy	424	484	
	HE	5 5 4 9 9 1 2	08/27/1996	Oshlack, et al.	424	468	
	HF	5 5 5 2 4 2 2	09/03/1996	Gauthier, et al.	514	368	
	HG	5 5 9 1 4 5 2	01/07/1997	Miller, et al.	424	468	
	HH	5 6 0 1 8 4 5	02/11/1997	Buxton, et al.	424	495	
	HI	5 6 2 2 7 2 2	04/22/1997	Knott, et al.	424	494	
	HJ	5 6 3 9 4 7 6	06/17/1997	Oshlack, et al.	424	468	
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	HK						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	HL	Loimer, et al., "Combined Naloxone/Methadone Preparations for Opiate Substitution Therapy"; J. of Substance Abuse Treatment (1991) Vol 8, pg. 157-160					
	HM	Martin, et al., "Bioavailability Investigation of a New Tilidine/Naloxone Liquid Formulation Compared to a Reference Formulation"; Arzneim.-Forsch./Drug Res. (1999) Vol 49, pg. 599-607					
	HN	Martin, et al., "Demonstration of Tolerance to and Physical Dependence on N-allylnormorphine (Nalorphine)"; J. of Pharm and Exper Thera (1965) Vol 150, No. 3, pg. 437-442					
	HO	Mendelson, et al., "Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers"; Psychopharmacology (1999) Vol 141, pg. 37-46					
	HP	Mendelson, et al., "Buprenorphine and Naloxone Interactions in Methadone Maintenance Patients"; Society of Biological Psychiatry (1997) Vol 41, pg. 1095-1101					
	HQ	Nutt, et al., "Methadone-naloxone mixtures for use in methadone maintenance programs"; Clin Pharma and Thera, Vol 15, No. 2, pg. 156-166 1973					
	HR	Parwatikar, et al., "Methadone-naloxone in combination for the treatment of heroin addicts"; Clin Pharm and Thera, Vol 14, No. 6, pg. 941-948 1973					
	EXAMINER			DATE CONSIDERED			
*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866								
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: October 21, 2003		GROUP: 1615								
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
g/s	IA	5	6	5	6	2	9	5	08/12/1997	Oshlack, et al.	424	468		
	IB	5	6	7	0	1	7	2	09/23/1997	Buxton, et al.	424	495		
	IC	5	6	7	2	3	6	0	09/30/1997	Sackler, et al.	424	490		
	ID	5	6	8	1	5	8	5	10/28/1997	Oshlack, et al.	424	494		
	IE	5	7	6	3	4	5	2	06/09/1998	Miller, et al.	514	282		
	IF	5	7	8	0	4	7	9	07/14/1998	Kim	514	282		
	IG	5	8	1	1	1	2	6	09/22/1998	Krishnamurthy	424	498		
	IH	5	8	3	4	4	7	7	11/10/1998	Mioduszewski	514	282		
g/s	II	5	8	4	3	4	8	0	12/01/1998	Miller, et al.	424	484		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	IJ													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
g/s	IK	Parwartikar, et al., "Naloxone-Methadone Combination for the Treatment of Opiate Dependence"; Missouri Institute of Psychiatry, pg. 1350-1354 1973												
	IL	Pitts, et al., "Antinociceptive and Response Rate-Altering Effects of <i>Kappa</i> Opioid Agonists, Spiradoline, Enadoline and U69,593, Alone and in combination with Opioid Antagonists in Squirrel Monkeys"; J. Pharm and Exper Thera (1994) Vol 271, No. 3, pg. 1501-1508												
	IM	Preston, et al., "Buprenorphine and Naloxone alone and in combination in opioid-dependent humans"; Psychopharmacology (1988) Vol 94, pg. 484-490												
	IN	Preston, et al., "Differential Naltrexone Antagonism of Hydromorphone and Pentazocine Effects in Human Volunteers"; J. Pharm and Exper Thera (1993) Vol 264, No. 2, pg. 813-823												
	IO	Preston, et al., "Effects of Sublingually given naloxone in opioid-dependent human volunteers"; Drug and Alcohol Dependence (1990) Vol 25, pg. 27-34												
	IP	Bigelow, et al., "Abuse Liability Assessment of Buprenorphine-Naloxone Combinations"; Dept. of Psychiatry and Behavioral Sciences - The Johns Hopkins University School of Medicine, pg. 145-149 1997												
g/s	IQ	Wikler, et al., 'N-Allylnormorphine: Effects of single doses and precipitation of acute "Abstinence Syndromes" during addiction to morphine, methadone or heroin in man (post-addicts)'; N-Allylnormorphine During Narcotic Addiction (1953) pg. 8-20												
EXAMINER  <i>Shunra Y. Brink</i>										DATE CONSIDERED  7/23/07				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.			
				FILING DATE: October 21, 2003		GROUP: 1615	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	JA	5 8 4 9 2 4 0	12/15/1998	Miller, et al.	264	460	
	JB	5 8 6 9 0 9 7	02/09/1999	Wong, et al.	424	473	
	JC	5 8 7 9 7 0 5	03/09/1999	Heafield, et al.	424	464	
	JD	5 8 9 1 4 7 1	04/06/1999	Miller, et al.	424	468	
	JE	5 9 0 8 8 4 8	06/01/1999	Miller, et al.	514	282	
	JF	5 9 5 8 4 5 2	09/28/1999	Oshlack, et al.	424	457	
	JG	5 9 5 8 4 5 9	09/28/1999	Chasin, et al.	424	490	
	JH	5 9 6 5 1 6 1	10/12/1999	Oshlack, et al.	424	457	
	JJ	5 9 6 5 1 6 3	10/12/1999	Miller, et al.	424	468	
	JJ	5 9 6 8 5 5 1	10/19/1999	Oshlack, et al.	424	456	
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	JK						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	JL	Zaks, et al., "Naloxone Treatment of Opiate Dependence"; JAMA (1971) Vol 215, No. 13, pg. 2108-2110					
	JM	Barton, et al., "Intranasal Administration of Naloxone by Paramedics"; Prehospital Emergency Care (2002) Vol 6, No. 1, pg. 54-58					
	JN	Blachly, Paul, H., M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pg. 209-213					
	JO	Bashaw, et al., "Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade"; Inter J. of Clin Pharm and Thera (1995) Vol 33, No. 9, 524-529					
	JP	Jasinski, D.R., "Assessment of the Abuse Potentiality of Morphinelike Drugs (Methods Used in Man)"; Drug Addiction (1977) pg. 197-258					
	JQ	Johnson, et al., "Buprenorphine and Naloxone for Heroin Dependence"; Substance Use Disorders (2000) pg. 519-526					
	JR	Strain, et al., "Opioid antagonist effects of dezocine in opioid-dependent humans"; Clin Pharm and Thera (1996) Vol 60, No. 2, pg. 206-217					
	EXAMINER 				DATE CONSIDERED 07/23/07		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.			
				FILING DATE: October 21, 2003		GROUP: 1615	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	KA	6 0 2 4 9 8 2	02/15/2000	Oshlack, et al.	424	476	
	KB	6 0 6 8 8 5 5	05/30/2000	Leslie, et al.	424	468	
	KC	6 0 7 7 5 3 2	06/20/2000	Malkowska, et al.	424	457	
	KD	6 0 7 7 5 3 3	06/20/2000	Oshlack, et al.	424	461	
	KE	6 1 0 3 2 5 8	08/15/2000	Simon	424	449	
	KF	6 1 0 3 2 6 1	08/15/2001	Chasin, et al.	424	459	
	KG	6 1 4 3 3 2 2	11/07/2000	Sackler, et al.	424	459	
	KH	6 1 4 3 3 2 8	11/07/2000	Heafield, et al.	424	489	
	KI	6 1 6 2 4 6 7	12/19/2000	Miller, et al.	424	468	
	KJ	6 2 1 0 7 1 4	04/03/2001	Oshlack, et al.	424	476	
	KK	6 2 5 4 8 8 7	07/03/2001	Miller, et al.	424	468	
	KL	6 2 6 1 5 9 9	07/17/2001	Oshlack, et al.	424	457	
	KM	6 2 9 4 1 9 5	09/25/2001	Oshlack, et al.	424	457	
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	KN	0 1 3 7 7 8 5	05/31/2001	WO (A2)	A61K		
	KO	0 1 5 2 8 5 1	07/26/2001	WO (A1)	A61K	31/485	
	KP	0 1 8 5 2 5 7	11/15/2001	WO (A2)	A61P		
	KQ	0 1 9 3 8 5 2	12/13/2001	WO (A2)	A61K	31/00	
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	KR	Preston, et al., "Abuse liability studies of opioid agonist-antagonists in humans"; Drug and Alcohol Dependence (1991) Vol 28, pg. 49-82					
	KS	Brennscheidt, et al., "Pharmacokinetics of Nortilidine and Naloxone after Administration of Tilidine/Naloxone Solution or Tilidine/Naloxone Sustained Release Tablets"; Arzneimittel-Forsch/Drug Res. (2000) Vol 50, pg. 1015-1022					
EXAMINER							
			DATE CONSIDERED <b>7/23/07</b>				
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866								
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: October 21, 2003		GROUP: 1615								
<b>U.S. PATENT DOCUMENTS</b>														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	LA	6	3	0	6	4	3	8	10/23/2001	Oshlack, et al.	424	468		
	LB	6	3	2	6	0	2	7	12/04/2001	Miller, et al.	424	468		
	LC	6	3	3	5	0	3	3	01/01/2002	Oshlack, et al.	424	457		
	LD	6	3	7	5	9	5	7	04/23/2002	Kaiko, et al.	424	400		
	LE	6	3	8	7	4	0	4	05/14/2002	Oshlack, et al.	424	480		
	LF	6	3	9	9	0	9	6	06/04/2002	Miller, et al.	424	464		
	LG	6	4	7	5	4	9	4	11/05/2002	Kaiko, et al.	424	400		
<b>FOREIGN PATENT DOCUMENTS</b>														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	LH													
	LI													
	LJ													
	LK													
	LL													
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
	LM													
	LN													
	LO													
	LP													
EXAMINER 										DATE CONSIDERED 7/23/07				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
200.1133CONSERIAL NO.:  
10/689,866

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):  
Oshlack, et al.FILING DATE:  
October 21, 2003GROUP:  
1615

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
g/s	MA	5	9	9	8	4	3	4	12/99	Mitch et al.	514	210.16	
	MB	5	9	7	2	9	5	4	10/99	Foss	514	282	
	MC	5	9	6	8	5	4	7	10/99	Reder et al.	424	449	
	MD	5	9	4	2	2	4	1	8/99	Chasin et al.	424	426	
	ME	5	8	8	0	1	3	2	3/99	Hill	514	282	
	MF	5	8	6	6	1	6	4	2/99	Kuczynski et al.	424	472	
	MG	5	8	6	0	9	5	0	1/99	Demopoulos et al.	604	49	
	MH	5	8	5	8	0	1	7	1/99	Demopoulos et al.	604	890.1	
	MI	5	7	6	7	1	2	5	6/98	Crain et al.	514	282	
	MJ	5	6	3	3	2	5	9	5/97	Qin et al.	514	282	
g/s	MK	5	6	2	4	9	3	2	4/97	Qin et al.	514	282	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
g/s	ML	19	6	5	1	5	5	1	6/98	DE	A61K	31/485		
	MM	29	7	1	9	7	0	4	2/97	DE	A61K	31/485		
g/s	MN	4	3	2	5	4	6	5	2/95	DE	A61K	31/485	X	
	MO	2	2	2	2	0	3	9	11/72	DE	A61K	27/00		
	MP	0	9	1	3	1	5	2	6/99	EP	A61K	31/485		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

g/s	MQ	Abstract, Cancer Chemother Pharmacol (1998); 42(4):287-91.											
	MR	Yuan et al., Drug and Alcohol Dependence (1998); 52:161-165.											
	MS	Gan et al., "Opioid-Sparing Effects of a Low-Dose Infusion of Naloxone in Patient-Administered Morphine Sulfate," Anesthesiology (1997), 87(5):1075-1080.											

EXAMINER

*James J. Driscoll*

DATE CONSIDERED

*7/23/07*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866								
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: October 21, 2003		GROUP: 1615								
<b>U.S. PATENT DOCUMENTS</b>														
*EXAMINER INITIAL	NA	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	NA	5	6	1	6	6	0	1	4/97	Khanna et al.	514	399		
	NB	5	5	8	5	3	4	8	12/96	Crain et al.	514	12		
	NC	5	5	8	0	8	7	6	12/96	Crain et al.	514	282		
	ND	5	5	7	8	7	2	5	11/96	Portoghese et al.	546	35		
	NE	5	5	7	4	0	5	2	11/96	Rose et al.	514	343		
	NF	5	5	5	6	8	3	8	9/96	Mayer et al.	514	25		
	NG	5	5	3	4	4	9	2	7/96	Aston et al.	514	608		
	NH	5	5	1	4	6	8	0	5/96	Weber et al.	514	249		
	NI	5	5	1	2	5	7	8	4/96	Crain et al.	514	282		
	NJ	5	5	0	2	0	5	8	3/96	Mayer et al.	514	289		
	NK	5	4	8	6	3	6	2	1/96	Kitchell et al.	424	426		
<b>FOREIGN PATENT DOCUMENTS</b>														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	NL	0	6	4	7	4	4	8	4/95	EP	A61K	31/485		
	NM	0	3	5	2	3	6	1	1/90	EP	A61K	31/485		
	NN	0	2	0	5	2	8	2	12/86	EP	A61K	9/22		
	NO	9	9	3	2	1	2	0	7/99	WO	A61K	31/485		
	NP	9	8	3	5	6	7	9	8/98	WO	A61K	31/485		
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
	NQ	Shen et al., "Ultra-Low Doses of Naltrexone or Etorphine Increase Morphine's Antinociceptive Potency and Attenuate Tolerance/Dependence in Mice," Brain Research (1997), 757:176-190.												
	NR	Yuan et al., Clinical Trials and Therapeutics (1997), 61:467-475.												
EXAMINER 										DATE CONSIDERED 7/23/07				
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>														

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
200.1133CONSERIAL NO.:  
10/689,866

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):  
Oshlack, et al.FILING DATE:  
October 21, 2003GROUP:  
1615

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
g/s	OA	5	4	7	2	9	4	3		12/95	Crain et al.	514	12	
	OB	5	4	5	7	2	0	8		10/95	Portoghese et al.	546	35	
	OC	5	4	2	6	1	1	2		6/95	Zagon et al.	514	282	
	OD	5	3	7	6	6	6	2		12/94	Ockert	514	282	
	OE	5	3	5	6	9	0	0		10/94	Bihari et al.	514	282	
	OF	5	3	5	2	6	8	3		10/94	Mayer et al.	514	289	
	OG	5	3	5	2	6	8	0		10/94	Portoghese et al.	514	279	
	OH	5	3	2	1	0	1	2		6/94	Mayer et al.	514	25	
	OI	5	3	1	7	0	2	2		5/94	Borsodi et al.	514	282	
	OJ	5	3	1	6	7	5	9		5/94	Rose et al.	424	10	
g/s	OK	5	2	7	3	7	6	0		12/93	Oshlack et al.	424	486	


## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
														YES	NO
g/s	OL	9	7	3	3	5	6	6		9/97	WO	A61K	9/20		
	OM	9	6	0	2	2	5	1		2/96	WO	A61K	31/485		
	ON	9	5	0	3	8	0	4		2/95	WO	A61K	31/485		
	OO	9	4	0	6	4	2	6		3/94	WO	A61K	31/46		
g/s	OP	8	3	0	3	1	9	7		9/83	WO	A61K	9/22		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

g/s	OQ	Mendelson J., et al., "Buprenorphine and Naloxone Interactions in Opiate-Dependent Volunteers," Clin. Phar. Ther. (1996), 60:105-114.
g/s	OR	Walsh et al., "Effects of Naltrexone on Response to Intravenous Cocain, Hydromorphone and their Combination in Humans," (1996).

EXAMINER



DATE CONSIDERED

7/23/87

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866								
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: October 21, 2003		GROUP: 1615								
<b>U.S. PATENT DOCUMENTS</b>														
*EXAMINER INITIAL	PA	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<i>9/8</i> <div style="border-left: 1px solid black; height: 100px; margin: 0 auto; width: 20px;"></div>	PA	5	2	5	6	6	6	9	10/93	Askanazi et al.	514	282		
	PB	5	2	3	6	7	1	4	8/93	Lee et al.	424	449		
	PC	5	2	2	5	4	4	0	7/93	London et al.	514	535		
	PD	5	1	4	9	5	3	8	9/92	Granger et al.	424	449		
	PE	5	1	0	2	8	8	7	4/92	Goldberg	514	282		
	PF	5	0	9	6	7	1	5	3/92	Sinclair	424	449		
	PG	5	0	8	6	0	5	8	2/92	Sinclair et al.	514	282		
	PH	5	0	7	5	3	4	1	12/91	Mendelson et al.	514	282		
	PI	4	9	3	5	4	2	8	6/90	Lewis	514	282		
	PJ	4	8	8	9	8	6	0	12/89	Rzeszotarski et al.	514	282		
<i>9/8</i> <div style="border-left: 1px solid black; height: 100px; margin: 0 auto; width: 20px;"></div>	PK	4	8	8	2	3	3	5	11/89	Sinclair	514	282		
<b>FOREIGN PATENT DOCUMENTS</b>														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	PL													
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
<i>9/8</i> <div style="border-left: 1px solid black; height: 100px; margin: 0 auto; width: 20px;"></div>	PM	Chih-Cheng Chien, Neuroscience Letters 190 (1995), 137-139.												
	PN	Crain et al., "Ultra-Low Concentrations of Naloxone Selectively Antagonize Excitatory Effects of Morphine on Sensory Neurons, Thereby Increasing Its Antinociceptive Potency and Attenuating Tolerance/Dependence During Chronic Cotreatment," Proc. Natl. Acad. Sci. USA (1995), 92:10540-10544.												
	PO	Hanson, Analgesic, Antipyretic and Anti-Inflammatory Drugs in Remington's Science and Practice of Pharmacy (1995), 2:1207.												
	PP	Physician's Desk Reference 48 <sup>th</sup> Ed. (1994) Montvale, NJ, 2120-2121.												
<i>9/8</i> <div style="border-left: 1px solid black; height: 100px; margin: 0 auto; width: 20px;"></div>	PQ	Foss et al., J. Clin Pharmacol (1993), 33:747-751.												
EXAMINER										DATE CONSIDERED				
										<i>7/23/07</i>				
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>														



FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.			
				FILING DATE: October 21, 2003		GROUP: 1615	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	QA	4 8 7 3 0 7 6	10/89	Fishman et al.	412	10	
	QB	4 8 6 1 7 8 1	8/89	Goldberg	514	282	
	QC	4 8 6 1 5 9 8	8/89	Oshlack et al.			
	QD	4 8 0 6 5 5 8	2/89	Wuest et al.	514	381	
	QE	4 8 0 6 5 4 3	2/89	Choi	514	464	
	QF	4 8 0 6 3 4 1	2/89	Chien et al.	424	448	
	QG	4 8 0 3 2 0 8	2/89	Pasternak	514	282	
	QH	4 7 8 5 0 0 0	11/88	Kreek et al.	514	282	
	QI	4 7 6 9 3 7 2	9/88	Kreek et al.	514	282	
	QJ	4 7 6 0 0 6 9	7/88	Rzeszotarski et al.	514	282	
	QK	4 7 3 0 0 4 8	3/88	Portoghese et al.	546	45	
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	QL						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	QM	Holmes et al., Anesth. Analg. (1993), 77:1166-73.					
	QN	Mlaskowski et al., Brain Research (1992), 596:41-45.					
	QO	Weinhold et al., "Buprenorphine Alone and In Combination with Naltrexone in Non-Dependent Humans," Drug and Alcohol Dependence (1992), 30:263-274.					
	QP	Cappel et al., Pharma. Bioch. & Behav. (1989), 34:425-427.					
	QQ	Vaccarino et al., Pain (1989), 36:103-109.					
	QR	Gonzalez et al., "Naltrexone: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Opioid Dependence," Drugs (1988), 35:192-213.					
EXAMINER 				DATE CONSIDERED 07/23/07			
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866								
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: October 21, 2003		GROUP: 1615								
<b>U.S. PATENT DOCUMENTS</b>														
*EXAMINER INITIAL	RA	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	RB	4	7	1	9	2	1	5	1/88	Goldberg	514	282		
	RC	4	6	0	8	3	7	6	8/86	Pasternak	514	282		
	RD	4	5	8	2	8	3	5	4/86	Lewis et al.	514	282		
	RE	4	5	7	3	9	9	5	3/86	Chen et al.	604	896		
	RF	4	4	6	4	3	7	8	8/84	Hussain et al.	424	260		
	RG	4	4	5	7	9	3	3	7/84	Gordon et al.	424	260		
	RH	4	4	5	1	4	7	0	5/84	Ganti	424	260		
	RI	4	4	0	1	6	7	2	8/83	Portoghese et al.	424	260		
	RJ	4	1	7	6	1	8	6	11/79	Goldberg	424	260		
		RK	3	9	6	6	9	4	0	6/76	Pachter et al.	424	260	
<b>FOREIGN PATENT DOCUMENTS</b>														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	RL													
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
	RM	Sunshine, et al., "Analgesic Efficacy of Pentazocine Versus a Pentazocine-Naloxone Combination Following Oral Administration," Clin. J. Pain (1988), 4:35-40.												
	RN	Wang et al., "Crossover and Parallel Study of Oral Analgesics," J. clin. Pharmacol (1981), 21:162-168.												
	RO													
	RP													
	RQ													
	RR													
EXAMINER										DATE CONSIDERED				
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.			
				FILING DATE: October 21, 2003		GROUP: 1615	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	SA	3 8 7 9 5 5 5	4/75	Pachter et al.	424	260	
	SB	3 7 7 3 9 5 5	11/73	Pachter et al.	424	260	
	SC	3 6 7 6 5 5 7	7/72	Lachman et al.	424	260	
	SD	3 4 9 3 6 5 7	2/70	Lewenstein et al.	424	260	
	SE	3 3 3 2 9 5 0	7/67	Blumberg et al.	260	285	
	SF	2 7 7 0 5 6 9	11/56	Fromherz et al.	167	65	
	SG	6 0 0 4 9 7 0	12/99	O'Malley et al.	514	282	
	SH	6 1 2 0 8 0 6	9/00	Whitmire	424	497	
	SI	6 5 7 9 5 3 6	06/03	Hirsch et al.	424	484	
	SJ	6 6 0 8 0 7 5	08/03	Foss et al.	514	282	
	SK	6 7 1 6 4 4 9	04/04	Oshlack et al.	514	002	
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	SL						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	SM	Benfey, Function of Myocardial $\alpha$ -ADRENOCEPTORS: Life Sciences (1982) Vol. 31 pg 101-112					
	SN	Levine, et al., Potentiation of Pentazocine Analgesia by Low-dose Naloxone: J. Clin. Invest. (1988) Vol. 82 pg. 1574-1577					
	SO	Yobum, et al., Opioid Antagonist-induced Receptor Upregulation: Effects of Concurrent Agonist Administration, (1994) (Publication Date): Brain Research Bulletin, Vol. 33 pg 237-240					
	SP	Bunzow, et al., Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a $\mu$ , $\delta$ or $\kappa$ opioid receptor type: FEBS Letters 347 (1994) pg. 284-288					
	SQ	Mollereau, et al., ORL1, a novel member of the opioid receptor family: Cloning, functional expression and localization: FEBS Letters 341 (1994) pg. 33-38					
	SR	Wang, et al., cDNA cloning of an orphan opiate receptor gene family member and its splice variant: FEBS Letters 348 (1994) 75-79					
	SS	Suzuki, et al., Morphine conditioned place preference after chronic treatment with naloxone in the rat: Research Communications in Substances of Abuse. (1991) Vol. 12, No. 3 pg. 119-131					
EXAMINER			DATE CONSIDERED				
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866								
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: October 21, 2003		GROUP: 1615								
<b>U.S. PATENT DOCUMENTS</b>														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	TA	6	2	2	8	8	6	3	05/08/01	Palermo et al.	514	282		
	TB	6	2	7	7	3	8	4	08/21/01	Kaiko et al.	424	400		
	TC	6	6	2	7	6	3	5	09/03	Palermo et al.	514	282		
	TD	6	6	9	6	0	6	6	02/04	Kaiko et al.	424	400		
	TE	6	4	7	5	4	9	4	11/02	Kaiko et al.	424	400		
	TF	7	1	4	4	5	8	7	12/06	Oshlack et al.	424	490		
<b>FOREIGN PATENT DOCUMENTS</b>														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	TG	WO	98	2	5	6	1	3	06/18/98	EPO	A61K	31/485		X
	TH	WO	00	3	8	6	4	9	07/06/00	EPO	A61K	9/00		X
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
	TI	Life Sci. 1982 31 pg 101-104												
	TJ	J Pharm. Exper. Ther. 1991 259(2) pg 582-589												
	TK	Pharmacol. Bio. Beh. 1995 51 (2) pg 535-539												
	TL	J. Clin. Invest. 1988 82(5) pg 1574-1577												
	TM	Brain Res. 2001 888 pg 75-82												
	TN	Res. Comm. Sust. Abuse 1991 12(3) pg 119-131												
	TO	Brain Res. Bull. 1994 33(2) pg 237-240												
	TP	FEBS Lett. 1994 347, pg 284-288												
	TQ	FEBS Lett. 1994 341 pg 33-38												
	TR	FEBS Lett. 1994 348 pg 75-79												
	TS	Neuroscience 1998 82, pg 223-240												
	TT	J. Neuro Sci 1998 18, pg 9685-9694												
	TU	Neurosci. Lett. 1999 272, pg 183-186												
	TV	Eur. J. Pharmacol. 2000 404, pg 153-159												
EXAMINER 										DATE CONSIDERED 7/23/07				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
200.1133CONSERIAL NO.:  
10/689,866

OTHER PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):  
Benjamin OSHLACK et al.FILING DATE:  
October 21, 2003GROUP:  
1615

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AI							

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

/HS/	AJ	Philip D. Kanof et al., "Levels of Opioid Physical Dependence in Heroin Addicts," Drug and Alcohol Dependence, 27 (1991) 253-262.
/HS/	AK	J.E. Peachey et al., "Assessment of Opioid Dependence with Naloxone," British Journal of Addiction (1988) 83(2), 193-201
/HS/	AL	John G. Nutt et al., "Methadone-naloxone Mixtures for Use in Methadone Maintenance Programs," Clinical Pharmacology and Therapeutics, Vol. 15, Number 2, pp. 156-166, received for publication June 11, 1973
/HS/	AM	Richard I. H. Wang et al., "Rating the Presence and Severity of Opiate Dependence," Clinical Pharmacology and Therapeutics, Volume 16, Number 4, pp. 653-657; received for publication January 21, 1974
/HS/	AN	Richard B. Resnick et al., "Naloxone Precipitated Withdrawal: A Method For Rapid Induction Onto Naltrexone," Clinical Pharmacology and Therapeutics, Volume 21, Number 4, pp. 409-413; received for publication November 16, 1976
/HS/	AO	Barbara A. Judson et al., "The Naloxone Test Opiate Dependence," Clin. Pharmacol. Ther., Vol. 27, Number 4, pp. 492-501, received for publication September 15, 1979
/HS/	AP	Philip D. Kanof et al., "Clinical Characteristics of Naloxone-Precipitated Withdrawal in Human Opioid-Dependent Subjects," The Journal of Pharmacology and Experimental Therapeutics, Vol. 260, No. 1, pp. 355-363, 1992
/HS/	AQ	Richard L. Wiesen et al., "The Safety and Value of Naloxone as a Therapeutic Aid," Drug and Alcohol Dependence, 2 (1977) pp. 123-130
	AR	
	AS	

EXAMINER

/Humera Sheikh/

DATE CONSIDERED

07/23/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.